Small-Vessel Stroke Risk and Your Genetics
Authored by the ExomeDNA Science Team | Last reviewed 2026-05-29
This page contains general information only. For personal health decisions, consult a qualified clinician.
Small-vessel stroke risk is a genetically influenced trait reflecting how your DNA affects the structural integrity of the brain's smallest arteries and the platelet biology that governs clotting within them. A large 2018 multi-ancestry genome-wide meta-analysis (PMID 29531354) mapped 32 loci to stroke subtypes across more than 520,000 participants, identifying specific variants near genes such as COL4A2, CASZ1, SH2B3, NBEAL1, CAMK2D, ATXN2, JPH3, PMF1, and SH3PXD2A as contributors to small-vessel ischemic stroke susceptibility. Below: what the genetics mean, what the research shows, and how lifestyle choices intersect with this result.
What is small-vessel stroke risk?
Stroke is not a single disease. Clinicians divide ischemic stroke into subtypes based on which arteries are affected and the underlying mechanism. Small-vessel stroke — also called lacunar stroke or lacunar infarction — occurs when one of the brain's tiny penetrating arteries (typically 50–400 micrometres in diameter) becomes occluded or damaged. These vessels supply deep brain structures including the basal ganglia, thalamus, internal capsule, and pons. When they fail, the resulting infarcts are typically small (under 15 mm) but can cause disproportionately disabling symptoms: weakness on one side, slurred speech, loss of sensation, or subtle cognitive changes.
Small-vessel stroke accounts for roughly 25% of all ischemic strokes in high-income countries. Unlike large-vessel atherosclerotic stroke or cardioembolic stroke (where clots travel from the heart), small-vessel stroke is driven by a distinct biology: chronic hypertensive arteriolar damage, lipohyalinosis of vessel walls, endothelial dysfunction, and local platelet-driven thrombosis in narrow lumens.
Your ExomeDNA result for this trait reflects polygenic risk — the aggregate effect of multiple common genetic variants that influence vessel wall architecture, platelet function, vascular tone, and blood pressure regulation. A higher score on a detrimental scale means your genetic background is modestly associated with elevated susceptibility to this subtype of stroke. It does not predict that a stroke will occur; genetic risk is one input among many, and lifestyle and medical management are powerful counterweights.
ICD-10 reference codes for this condition: I63.5 (cerebral infarction due to unspecified occlusion of cerebral arteries) and I63.81 (small vessel occlusion).
The genetics behind small-vessel stroke risk
Nine genes are implicated in this trait based on GWAS evidence. Each contributes through a distinct biological mechanism:
COL4A2 — the headline structural gene. Collagen type IV alpha-2 chain is the central scaffold protein of all basement membranes — the thin extracellular matrix sheets that surround blood vessels and separate tissue compartments. In small cerebral arteries, type IV collagen gives vessel walls mechanical strength and flexibility. When common variants near COL4A2 subtly reduce the quality or quantity of this collagen network, small penetrating arteries become more vulnerable to both thrombotic occlusion and hemorrhagic transformation under sustained blood pressure load. Rare high-impact mutations in COL4A1 and COL4A2 cause monogenic familial small-vessel cerebrovascular disease; the GWAS variants are common, lower-penetrance versions of the same biology.
CASZ1 — vascular development and blood pressure. CASZ1 encodes a zinc-finger transcription factor expressed in vascular endothelium and the heart. Genome-wide studies have repeatedly linked CASZ1 variants to blood pressure. Because hypertension is the single most important modifiable risk factor for small-vessel stroke, a genetic contribution to blood pressure regulation translates directly into small-vessel stroke susceptibility.
SH2B3 (LNK) — platelet production and inflammatory signaling. SH2B3 encodes the adaptor protein LNK, a negative regulator of JAK2 and thrombopoietin receptor signaling. It constrains both platelet production and inflammatory cytokine cascades. Loss-of-function variants in SH2B3 raise platelet counts and amplify platelet activation — both relevant to the thrombotic mechanism of small-vessel occlusion. SH2B3 variants also influence erythropoiesis and myeloproliferative disease susceptibility, underscoring the overlap between blood cell biology and stroke.
NBEAL1 — platelet granule secretion. Neurobeachin-like 1 is expressed in megakaryocytes and platelets, where it governs granule biogenesis and secretion. Platelet granule contents — ADP, serotonin, coagulation factors — are central amplifiers of thrombus formation. Variants in NBEAL1 alter platelet secretory function and thrombotic potential.
CAMK2D — vascular tone and calcium signaling. Calcium/calmodulin-dependent protein kinase 2, delta subtype, is expressed in vascular smooth muscle and cardiac tissue. It regulates how smooth muscle cells respond to calcium signals, influencing arterial contractility and tone. Dysregulation of vascular tone in small arteries contributes to ischemic vulnerability.
JPH3 — calcium release in vascular smooth muscle. Junctophilin 3 anchors the plasma membrane to the endoplasmic reticulum in smooth muscle cells, maintaining the tight junctional complexes through which calcium is released to drive vascular contraction. Disrupted JPH3 function impairs the precision of calcium-regulated vascular responses.
ATXN2 — mRNA regulation and stroke risk. Ataxin-2 is best known for its CAG repeat expansions causing spinocerebellar ataxia type 2 (SCA2), but common variants in the ATXN2 locus have been associated with ischemic stroke risk in GWAS. Ataxin-2 regulates mRNA translation and stress granule assembly; how these functions connect to cerebrovascular disease at the population level is an active area of research.
PMF1 — transcriptional regulation in vascular cells. Polyamine-modulated factor 1 acts as a transcriptional regulator expressed in vascular tissues. Its precise mechanistic contribution to small-vessel stroke biology awaits further functional characterization.
SH3PXD2A — extracellular matrix remodeling and vascular wall integrity. SH3 and PX domain-containing protein 2A organizes actin at podosomes — cell-matrix contact structures involved in extracellular matrix degradation and remodeling. Proper ECM remodeling is essential to maintaining vascular wall architecture under chronic hemodynamic stress.
What the research says
Research base: Moderate. The genetic associations underpinning this trait derive from a single large-scale study — the MEGASTROKE consortium meta-analysis (Malik et al., 2018; PMID 29531354) — which analyzed ischemic stroke subtypes across multiple cohorts encompassing more than 520,000 participants of multiple ancestries.
Stat block 1 — Study scale and loci identified. The MEGASTROKE analysis is among the largest stroke genetics efforts published to date. Across all ischemic stroke subtypes, 32 genome-wide significant loci were identified, with subtype-specific analyses isolating loci preferentially associated with small-vessel stroke (including variants near COL4A2, CASZ1, and SH2B3). The multi-ancestry design improves the generalizability of findings beyond European-only samples, though effect sizes and allele frequencies may differ across populations.
Stat block 2 — Population-level stroke incidence context. Globally, ischemic stroke is among the leading causes of death and long-term disability. Small-vessel stroke specifically accounts for approximately 20–25% of all first ischemic strokes. The 10-year recurrence risk following a first lacunar stroke is estimated between 10–20% in clinical studies, making primary and secondary prevention an active clinical priority. Polygenic risk scores for stroke subtypes are not yet in routine clinical use but are increasingly studied as a complement to traditional risk calculators such as the Framingham Stroke Risk Score.
The moderate evidence tier reflects the single-PMID constraint for this trait. While the MEGASTROKE study is methodologically robust — pre-registered, multi-ancestry, large N — independent replication across separate study designs specifically for small-vessel stroke loci remains limited in the published literature available for this trait card. Biological plausibility for COL4A2, CASZ1, and SH2B3 is strong based on Mendelian disease genetics and functional studies, lending confidence to those specific loci even under single-GWAS constraints.
How small-vessel stroke risk affects you
Your result represents a polygenic score — the sum of many small genetic nudges, each individually modest. No single variant in this profile is deterministic. What the score reflects is a tendency for your baseline biology to sit slightly higher or lower on a population distribution of small-vessel stroke susceptibility.
The mechanisms are distributed: some of these genes affect whether your cerebral vessel walls are structurally resilient under blood pressure load (COL4A2, SH3PXD2A, CAMK2D, JPH3); others influence whether platelet activity in narrow vessels trends toward aggregation (SH2B3, NBEAL1); and still others affect blood pressure set points (CASZ1) or vascular gene expression more broadly (PMF1, ATXN2).
Importantly, the dominant environmental driver of small-vessel stroke — sustained hypertension — is highly modifiable. The vessel wall changes that predispose to lacunar infarction develop over years of elevated pressure, which is why blood pressure management intervenes in the causal chain that genetic variants set in motion. A person with an elevated genetic score who maintains optimal blood pressure and lifestyle factors may face lower absolute risk than someone with a lower genetic score who has untreated hypertension, type 2 diabetes, and smokes.
This trait result is most useful as a prompt for earlier engagement with your primary care clinician regarding blood pressure monitoring, cardiovascular risk discussion, and stroke prevention habits — not as a verdict on whether a stroke will or will not occur.
Working with your small-vessel stroke risk result
If your result indicates elevated genetic susceptibility, the following evidence-based lifestyle and clinical levers have the strongest mechanistic connection to small-vessel stroke prevention:
Control blood pressure to below 130/80 mmHg. Hypertension is the single most important modifiable risk factor for small-vessel stroke. The vessel wall deterioration that leads to lacunar infarction — lipohyalinosis, fibrinoid necrosis — is driven by chronic pressure overload. Consistent blood pressure measurement at home (2x daily for at least one week before clinical visits) provides more accurate data than single-office readings. Discuss medication options with your clinician if lifestyle changes alone do not achieve target.
Eliminate or significantly reduce tobacco use. Smoking triples ischemic stroke risk through multiple mechanisms: endothelial damage, increased platelet aggregation, oxidative stress on vessel walls, and accelerated atherosclerosis. These mechanisms are particularly relevant to the genes in this profile (SH2B3/platelet pathway, SH3PXD2A/ECM integrity). Smoking cessation at any age produces measurable risk reduction within months.
Achieve at least 150 minutes of moderate aerobic activity per week. Regular physical activity is associated with approximately 25–30% reduced stroke risk in observational data, through blood pressure lowering, improved endothelial function, reduced platelet aggregability, and metabolic benefits. Walking, swimming, and cycling all count. Activity targets should be tailored by your clinician for those with existing cardiovascular conditions.
Reduce dietary sodium to under 2,300 mg/day (ideally closer to 1,500 mg/day). Dietary sodium reduction directly lowers blood pressure, protecting the cerebrovascular integrity that COL4A2 and other structural genes maintain. This is achievable through reducing processed and restaurant foods rather than eliminating added salt at home, which contributes a minority of total dietary sodium.
Screen and treat sleep apnea. Untreated obstructive sleep apnea causes intermittent hypoxia and surges in blood pressure during the night, contributing to endothelial damage and stroke risk. Those with snoring, daytime fatigue, or witnessed apneas should discuss formal sleep evaluation with their clinician. CPAP therapy in those with moderate-to-severe OSA reduces nocturnal blood pressure spikes.
Monitor for atrial fibrillation. While this trait primarily reflects small-vessel (lacunar) stroke biology, AF contributes to cardioembolic stroke and may be superimposed on pre-existing small-vessel vulnerability. Annual ECG in those with hypertension, age over 50, or relevant family history enables early detection. Wearable devices with FDA-cleared AF detection can provide complementary monitoring.
Related traits and genes
COL4A2 connects this trait to the broader domain of cerebrovascular structural integrity. Readers interested in how collagen IV variants affect not only stroke but also white matter disease (cerebral small-vessel disease, leukoaraiosis) will find related content in the Neurological and Cognitive categories.
Hypertension genetic risk is a closely related trait on ExomeDNA: the same CASZ1 locus appears in blood pressure GWAS, and blood pressure is the dominant mediator between many stroke-risk loci and actual events. Reviewing your hypertension polygenic result alongside this small-vessel stroke result provides a more complete picture of your cardiovascular risk architecture.
Platelet function traits — influenced by SH2B3 and NBEAL1 — connect small-vessel stroke risk to the broader cardiovascular category. Platelet biology underlies myocardial infarction and venous thromboembolism risk as well; the same variants may appear across multiple trait categories.
Ataxin-2 (ATXN2) also appears in neurodegenerative disease contexts, including ALS risk modification and spinocerebellar ataxia. If ATXN2 appears in your neurological traits, the mechanisms there differ from the vascular mechanism summarized here.
Frequently asked questions
Q: Does a high score on this trait mean I will have a stroke? A: No. This score reflects a population-level tendency based on common genetic variants. It indicates modestly elevated statistical susceptibility compared to those with lower scores. Many people with elevated genetic risk never experience a stroke, and many strokes occur in people without elevated polygenic scores. Lifestyle, blood pressure control, and medical care are all powerful modifiers.
Q: Is small-vessel stroke different from other types of stroke? A: Yes. Small-vessel stroke (lacunar stroke) involves the tiny penetrating arteries of the deep brain and differs mechanistically from large-vessel atherosclerotic stroke (plaque rupture in major arteries) and cardioembolic stroke (clots from the heart). The genes in this ExomeDNA profile are specifically associated with the small-vessel subtype based on subtype-stratified GWAS analysis.
Q: Can genetics override blood pressure control? A: The genetic variants in this profile influence baseline biological tendencies — vessel wall resilience, platelet reactivity, blood pressure regulation — but they do not override the effect of sustained blood pressure control. Hypertension is the dominant causal driver of small-vessel disease, and the genetic variants in this profile appear to act partly through their influence on blood pressure pathways (particularly CASZ1). Achieving target blood pressure intervenes directly in the mechanism connecting genetic risk to outcomes.
Q: What is COL4A2 and why does it matter for stroke? A: COL4A2 encodes collagen type IV alpha-2 chain, a structural protein that forms the scaffold of basement membranes — the thin matrix layers surrounding every small blood vessel. In cerebral penetrating arteries, this collagen network provides mechanical resilience under the pulsatile pressure of the heartbeat. Variants that reduce COL4A2 structural integrity make small vessels more susceptible to both occlusion and rupture. This is the strongest single-gene mechanistic anchor in this trait.
Q: Should I take aspirin based on this result? A: Aspirin affects platelet aggregation — relevant to SH2B3 and NBEAL1 biology in this profile — but aspirin use for primary stroke prevention is a nuanced clinical decision that depends on your individual bleeding risk, age, cardiovascular history, and other factors. The decision should be made with your clinician rather than based on this genetic result alone. This page does not constitute guidance on aspirin use.
Q: How reliable is the science underlying this trait? A: The genetic associations come from the MEGASTROKE consortium (PMID 29531354), a meta-analysis of over 520,000 participants across multiple ancestries. This is a methodologically robust study. The confidence tier for this trait is moderate, reflecting that while the study is large and the biological mechanisms for several genes (especially COL4A2 and CASZ1) are well-supported, independent replication specifically for the small-vessel stroke subtype loci is more limited than for some other cardiovascular traits.
References
- Malik R, et al. Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes. Nature Genetics. 2018. PMID 29531354.
ExomeDNA genetic results are for wellness and educational purposes only. Consult a clinician for personalized health guidance.